ANCA-ASSOCIATED VASCULITIS: HETEROGENEITY OF CLINICAL MANIFESTATIONS, PROGNOSIS, CURRENT OPPORTUNITIES OF PHARMACOTHERAPY
Article PDF

Keywords

ANCA-associated vasculitis, granulomatosis with polyangiitis, clinical features, prognosis, immunobiological therapy, rituximab

Abstract views: 133
PDF Downloads: 123

How to Cite

Yaremenko, O., & L.B. (2017). ANCA-ASSOCIATED VASCULITIS: HETEROGENEITY OF CLINICAL MANIFESTATIONS, PROGNOSIS, CURRENT OPPORTUNITIES OF PHARMACOTHERAPY. Medical Science of Ukraine (MSU), 13(1-2), 98-105. https://doi.org/10.32345/2664-4738.1-2.2017.14

Abstract

The article highlights the new views on classification and nomenclature of systemic vasculitis, the meaning of detection of antineutrophil cytoplasmic antibodies (ANCA) in the diagnosis and prognosis of the disease. The literature data and own research regarding clinical manifestations of ANCA-associated vasculitis are presented.  Analyzing the first clinical manifestations in 41 patients with granulomatosis with polyangiitis, we identified four variants of the debut: with involvement of ENT organs (n ​=21), with lung lesions without involvement of the upper respiratory tract (n=8), with skin lesions, joint involvement and fever (n=7) and other variants (n=5). Fever (76%), involvement of ENT organs (51%), skin (41%), nervous system (39%) and arthritis/arthralgia (37%) were the most frequent first manifestations of granulomatosis with polyangiitis. In comparison with the presenting features there were more often lesions of the skin (66% vs. 41%), nervous system (51% vs. 39%), kidneys (41% vs. 10%), lungs (63% vs. 30%), eyes (32% vs. 10%) and myalgia (34% vs. 12%) throughout course of disease.  Among the lesions of the ENT organs, sinusitis (n=19), rhinitis (n=8) and otitis (n=6) were predominate, laryngotracheitis, sublottic stenosis, saddle-shaped deformation of the nose, destruction of the walls of the paranasal sinuses and mastoiditis were diagnosed less frequently. The latest clinical recommendations for treating patients with ANCA-associated vasculitis, including the use of immunobiological therapy are presented, as well as describing of the results of our own experience in the using of immunobiological therapy in patients with granulomatosis with polyangiitis.

https://doi.org/10.32345/2664-4738.1-2.2017.14
Article PDF

References

Almouhawis H., Leao J. Wegener's granulomatosis: a review of clinical features and an update in diagnosis and treatment // J. Oral Pathol. Med. 2013. Vol. 42, No. 7. Р. 507-516.

Anderson G. et al. Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee // Q. J. Med. 1992. Vol. 83. Р. 427-438.

Cartin-Ceba R., Singh E. Pituitary dysfunction in granulomatosis with polyangiitis // La Presse Médicale. 2013. Vol. 42. Р. 710-711.

Comarmond C., Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment // Autoimmun. Rev. 2014. Vol. 13. P. 1121-1125.

Craven A. et al. ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS) // Clin. Exp. Nephrol. 2013. Vol.17. P. 619-621.

Fauci A. Vasculitis // J. Allergy Clin. Immunol. 1983. Vol. 72, No. 3. Р. 211-223.

Flossmann O. et al. Long-term patient survival in ANCA-associated vasculitis // Ann. Rheum. Dis. 2011. Vol. 70, No. 3. Р. 488-494.

Fujimoto S. et al. Comparison of the epidemiology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis between Japan and UK // Rheumatology. 2011. Vol. 2010. P. 1916-1920.

Gonzalez-Gay M., Garcіa-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects // Medicine (Baltimore). 1999. Vol. 78, No. 5. Р. 292-308.

Guillevin L., Visser H., Noel L. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome – 62 patients // J. Rheumatol. 1993. Vol. 20. Р.1345-1349.

Hagen E. Standardisation of solid phase assays for ANCA determination // Nephrology. 1997. Vol. 3. Р.764-765.

Hoffman G. et al. Wegener granulomatosis: an analysis of 158 patients // Ann. Intern. Med. 1992. Vol. 116. Р.488-498.

Holle J. et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades // Arthritis Rheum. 2011. Vol. 63. Р. 257-266.

Jennette J.C. et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides // Arthritis & Rheumatism. 2013. Vol. 65. P. 1-11.

Kemna M. et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease // Am. Soc. Nephrol. 2015. Vol. 26. Р. 537-542.

Lightfoot R.W. et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa // Arthritis Rheum. 1990. Vol. 33. P. 88-93.

Lionaki S., Blyth Е., Hogan S. The Role of Antineutrophil Cytoplasmic Autoantibody Specificity for Myeloperoxidase or Proteinase 3 in Disease Recognition and Prognosis // Arthritis Rheum. 2012. Vol. 64. Р. 3452-3462.

Martinez-Morillo М., Grados D. Granulomatosis With Polyangiitis (Wegener). Description of 15 Cases // Reumatol. Clin. 2012. Vol. 8. P. 15-19.

Mukhtyar C., Guillevin L., Cid M. EULAR recommendations for the management of primary small and medium vessel vasculitis // Ann. Rheum. Dis. 2009. Vol. 68. Р. 310-307.

Ntatsaki E., Watts R.A., Scott D.G. Epidemiology of ANCA-associated vasculitis // Rheum. Dis. Clin. North. Am. 2010. Vol. 565. P. 447-461.

Radice A., Sinico R. Antineutrophil cytoplasmic antibodies (ANCA) // Autoimmunity. 2005. Vol. 38. Р. 93-103.

Ríos Blanco J., Gómez Cerezo J., Vázquez Muñoz E. Clinical-biological and radiological study of Wegener's granulomatosis in a university hospital // Rev. Clin. Esp. 2005. Vol. 205, No. 8. Р. 367-373.

Savige J. et al. Antineutrophil cytoplasmic antibodies and associated diseases: A review of the clinical and laboratory features // Kidney International. 2000. Vol. 57. P. 846-862.

Slot M. et al. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement // Kidney Int. 2003.Vol. 63. Р. 670-677.

Tural C. et al. Granulomatosis de Wegener: descripción de 6 pacientes // Med. Clin. 1992. Vol. 99, No. 5. Р. 63-66.

Yates M., Watts R., Bajema I. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis // Ann. Rheum. Dis. 2016. Vol. 75, No. 9. P. 1583-1594.

Watts R.A., Scott D.G.I. Epidemiology of vasculitis. Vasculitis. 2nd ed. // Oxford University Press. 2008. Vol. 250. P. 7-22.

Watts R.A. Vasculitis in Clinical / Practice Oxford University Press. 2008. P. 4-5.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.